|
|
Upfront Briefing
Risk ripped Monday — Trump and Tehran sketched a ceasefire, the Strait of Hormuz reopened, oil slid ~5%, and the S&P printed a record. Biotech actually got invited to the party for once, with XBI up nearly 2%. The science did the talking underneath: Intellia turned in the first phase 3 win for one-shot in vivo CRISPR, Spyre's TL1A antibody cleared phase 2 in colitis and lit up the takeout chatter — and Neumora's navacaprant went 0-for-3 in depression, taking a third of staff with it. One tape, every outcome.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,554.29 |
1.65% |
10.2% |
| Nasdaq 100 |
30,543.92 |
3.06% |
21.2% |
| Russell 2000 |
2,965.09 |
0.72% |
18.2% |
| Healthcare (XLV) |
152.89 |
(0.60%) |
(1.7%) |
| Biotech (XBI) |
136.40 |
1.95% |
12.2% |
| Nasdaq Biotech (NBI) |
5,979.46 |
0.69% |
4.8% |
| Clinical Trials (BBC) |
43.63 |
1.40% |
16.1% |
|
- Biotech rode the risk-on tape — XBI +1.95%, outpacing large-cap healthcare, which slipped (XLV −0.60%) — as EHA and ENDO kept catalyst flow heavy, led by Intellia's HAE win and Lilly's Jaypirca CLL combo.
- The rally was macro-led: a preliminary U.S.–Iran ceasefire and reopened Strait of Hormuz sent crude down ~5%, pushing the S&P +1.65% to a record and the Nasdaq Composite +3.07%.
- Market data: U.S. cash close Monday, 15 June 2026.
The Big 3
|
1
|
Intellia's one-shot CRISPR clears its phase 3 secondaries in HAE
|
- Intellia (NTLA) reported additional phase 3 Haelo data for lonvoguran ziclumeran (lonvo-z), its in vivo CRISPR therapy for hereditary angioedema: an 89% reduction in attacks requiring on-demand treatment and a 91% cut in moderate-to-severe attacks (weeks 5–28), plus a 17-point AE-QoL gain — on top of the 87% attack-reduction primary it hit six weeks ago. Simultaneous NEJM publication; rolling BLA underway, launch targeted for 1H 2027.
- Why it matters: This is the first phase 3 package showing in vivo CRISPR works as a one-time fix, and the stock moved on it Monday. The competitive read is brutal for the incumbents: Ionis's Dawnzera (81% reduction), Takeda's Takhzyro and BioCryst's Orladeyo all dose chronically, while lonvo-z is a single administration. Platform read-through runs straight to the editing group (CRSP, BEAM, VERV), where the bear case has always been whether in vivo editing translates. The catch: n=80, limited follow-up, a hand-picked cohort, and the durability and reimbursement questions every one-and-done therapy carries until real-world data lands.
- Source: Fierce Biotech
- More: Intellia IR
|
|
2
|
Neumora's navacaprant goes 0-for-3, ending the program and a third of staff
|
- Neumora (NMRA) said its phase 3 Koastal-2 and Koastal-3 studies of navacaprant in major depressive disorder missed both primary and key secondary endpoints on MADRS at week 6 — in Koastal-3, placebo numerically outperformed the drug. Neumora is discontinuing the kappa-opioid receptor antagonist and cutting ~35% of staff for ~$10M in annual savings, extending runway into Q3 2027. The stock fell ~45% Monday to $0.98, down roughly 95% from its early-2025 peak after Koastal-1 first missed.
- Why it matters: A clean three-trial sweep closes the book on kappa-opioid antagonism in depression and removes the entire bull thesis on the name — what's left is a sub-dollar shell with a rebuild pipeline: NMRA-511 (Alzheimer's agitation), the M4 PAM NMRA-898 (schizophrenia) and the NLRP3 inhibitor NMRA-215 (obesity). The broader read is the one MDD investors keep relearning — high placebo response makes antidepressant phase 3s a coin flip regardless of mechanism, and capital for novel CNS shots gets pricier after each miss. At $0.98 with runway only into Q3 2027, the financing and listing clock now drives the story more than the science.
- Source: Fierce Biotech
- More: Neumora IR
|
| 3 | Spyre's TL1A antibody hits in phase 2 UC, feeding the takeout math |
- Spyre's (SYRE) anti-TL1A antibody SPY002 met all key objectives in Part A of its phase 2 Skyline program in moderate-to-severe ulcerative colitis: a statistically significant 10.7-point reduction in Robart's Histopathology Index at week 12, a 33% clinical remission rate and 42% endoscopic improvement (n=48). It builds on April's SPY001 (anti-α4β7) readout — a 9.2-point RHI cut and 40% remission — with SPY003 (anti-IL-23) Part A data due in Q3 and combination arms now enrolling in Part B.
- Why it matters: TL1A is where big pharma has been writing the biggest immunology checks — Merck paid ~$10.8B for Prometheus's tulisokibart, Roche took Telavant's RVT-3101 for ~$7.1B upfront — so a clean phase 2 from a public, pure-play TL1A name lands as much like an M&A setup as a clinical update. Spyre's real edge is the combination thesis: pairing TL1A, α4β7 and IL-23 from one shop to leapfrog single-mechanism incumbents like Takeda's Entyvio (which SPY001 targets head-on) and AbbVie's Skyrizi/Rinvoq. The risk is that Part A is single-dose, small and histology-based — the test is whether Part B's combinations hold efficacy and safety. Mizuho already floated "potentially unprecedented" combo remission rates, which sets the bar high.
- Source: Fierce Biotech
- More: Spyre IR
|
Everything Else that broke
- Minghui's subcutaneous anti-IGF-1R antibody MHB018A posted 81% Week 12 active TED response and 76% Week 24 chronic TED response. — PR
- The FDA granted accelerated approval expanding Sanofi's Tzield (teplizumab) to newly diagnosed stage-3 type 1 diabetes patients ages 8–17 (Protect, n=328) — ~2 months past target, after Sanofi pulled the bid from the controversial CNPV voucher program amid CDER turmoil. — Fierce Pharma
- Rhythm highlighted six-month setmelanotide data supporting a Phase III path in Prader-Willi syndrome. — BioCentury
- Soleno's VYKAT XR showed durable Prader-Willi benefits through two years after randomized withdrawal. — PR
- FDA will keep Makary-era priorities on trials and China, a deputy said. — Endpoints
- Lilly's Jaypirca (pirtobrutinib) added to venetoclax + rituximab cut progression-or-death risk 45.3% in R/R CLL/SLL in phase 3 Bruin CLL-322 (n=639), with a 67.7% PFS benefit in the post-covalent-BTK subgroup (EHA). — Fierce Pharma
- A Delaware jury found Amgen and its acquired Teneobio willfully infringed a Harbour Antibodies patent, awarding $20.2M — potentially trebled to $60.6M. — Fierce Biotech
- Adaptive Biotechnologies plans to separate its MRD and Immune Medicine businesses into two companies. — PR
- CMS proposed codifying how related drugs are grouped under the Medicare Drug Price Negotiation Program, with implications for lifecycle-management and line-extension value. — CMS
- PTC Therapeutics priced 0% convertible notes to refinance its 2026 converts at a $107.48 conversion price (40% premium) — liability management, not fresh capital. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- No notable M&A or BD&L in the last 24 hours.
VC / Private Financings
- No notable VC or private financings in the last 24 hours.
IPOs / Follow-Ons
- Alvotech (ALVO) priced an upsized ~$152M raise — 22,666,667 shares at $3.75 (~$85M) plus a ~$67M concurrent private placement. — GlobeNewswire
- Enliven (ELVN) closed its upsized public offering, with underwriters exercising the full additional-share option. — PR
Academic Corner - Adaptive deep brain stimulation synchronized to gait phase was feasible, safe and reduced falls versus continuous stimulation in Parkinson's disease. — Nature Medicine
|
That's the tape — one peace deal, one CRISPR milestone, and one biotech that should've stayed in bed. — BioBucks Team
|
|
|
